All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
As a leading provider of Chimeric Antigen Receptor (CAR) field, Creative Biolabs provides CellRapeutics™ VHH-based CAR construction service according to diverse needs in different scientific projects. VHH-based chimeric receptor is considered as the fourth generation of CAR, which has been successfully studied in cancer targeting researches.
VHH (Nb) is the variable domain of heavy-chain antibodies (also as known as VHH). It is the smallest antibody fragment with complete function. Generally, it only has half the molecular weight of a single-chain variable fragment (scFv), which is able to trigger an immune response. The advantage of Nb is its lower immunogenicity and better pharmacokinetics as a result of its small size and high affinity to target antigen. VHH-based conjugates such as Nb-enzyme, Nb-exotoxin or Nb-T cell are becoming potential strategies applied in tumor targeting treatment.
Technically, we can generate an Nb gene library derived from lymphocytes of camels, and then screen this Nb library with tumor associated antigens. After isolating the specific Nb, we will construct CAR-T cells with this specific-Nb (VHH-based CAR) instead of a scFv, which is different from classical CAR. Furthermore, we can also generate humanized camelid Nb according to your specific needs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION